U.S. markets closed
  • S&P Futures

    4,405.25
    +10.50 (+0.24%)
     
  • Dow Futures

    34,777.00
    +87.00 (+0.25%)
     
  • Nasdaq Futures

    15,102.00
    +28.50 (+0.19%)
     
  • Russell 2000 Futures

    2,200.40
    +8.70 (+0.40%)
     
  • Crude Oil

    68.29
    +0.14 (+0.21%)
     
  • Gold

    1,813.20
    -1.30 (-0.07%)
     
  • Silver

    25.40
    -0.07 (-0.26%)
     
  • EUR/USD

    1.1839
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.1840
    +0.0080 (+0.68%)
     
  • Vix

    17.97
    -0.07 (-0.39%)
     
  • GBP/USD

    1.3892
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.6100
    +0.1420 (+0.13%)
     
  • BTC-USD

    39,799.30
    +1,357.82 (+3.53%)
     
  • CMC Crypto 200

    981.48
    +54.71 (+5.90%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,734.24
    +150.16 (+0.54%)
     

Global Psoriatic Arthritis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

·2 min read

DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Psoriatic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Psoriatic Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Psoriatic Arthritis market.

It covers emerging therapies for Psoriatic Arthritis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Psoriatic Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Psoriatic Arthritis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Psoriatic Arthritis pipeline products by the company.

Short-term Launch Highlights:

Find out which Psoriatic Arthritis pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Psoriatic Arthritis phase 3 clinical trial pipeline products

  • Psoriatic Arthritis phase 2 clinical trial pipeline products

  • Psoriatic Arthritis phase 1 clinical trial pipeline products

  • Psoriatic Arthritis preclinical research pipeline products

  • Psoriatic Arthritis discovery stage pipeline products

  • Psoriatic Arthritis pipeline products short-term launch highlights

Countries Covered

  • Global

  • Europe

  • US

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/2y19qe

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005629/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900